Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
A gene therapy for deafness is starting to deliver real-world benefit. Also, ultra-cheap telehealth options are raising concerns about whether easier access to prescription drugs is coming at the expense of patient care. And, in front of Congress, RFK Jr. seems to be striking a different tune on vaccines.
Sanofi research priorities in flux as new CEO logs in
From my colleague Andrew Joseph: One of the open questions about the future of Sanofi as Belén Garijo takes over as CEO this month is whether the company, which had upped its focus in immunology in recent years only to come up with lackluster results, will rebalance its priorities.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
